If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
21/02/2026 [07:16:00]
Results 50 to 75 of 104
Absstract of: AU2024308469A1
Disclosed are glycanic compounds and their use for treating or inhibiting the development of a viral infection in a subject, especially a coronavirus infection, such as a SARS-CoV-2 infection, or for treating conditions associated with viral infections, such as an acute inflammatory condition, cytokine release syndrome (CRS) or a cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).
Absstract of: AU2024303786A1
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).
Absstract of: WO2026017760A1
5 A composition in oral dosage form comprises tryptophan or at least one tryptophan intermediate, and at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and/or (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. The composition may include a cohort of bacteria 10 including at least one bacterium that (a) expresses enzymes of the shikimate pathway and is capable of producing tryptophan and at least one bacterium that (b) expresses enzymes of the indole pathway and is capable of producing one or more immunomodulatory metabolites. Typically, the cohort of bacteria is capable of producing the immunomodulatory indole derivatives indole-3-lactic acid (ILA), 15 indole-3-propionic acid (IPA) and indole acrylic acid (IA). The composition finds utility in inhibition or prevention of immune-mediated inflammatory damage in subjects with an immune-mediated infectious or non-infectious disease, and in particular can prevent a severe inflammatory response or incidence of Long Covid in SARS-CoV-19 subjects. 20 (Figure 16)
Absstract of: EP4682890A2
A messenger RNA (mRNA) vaccine has emerged as a promising direction to combat the COVID-19 pandemic. This requires an mRNA sequence that is stable and highly productive in protein expression, features to benefit from greater mRNA secondary structure folding stability and optimal codon usage. Sequence design remains challenging due to the exponentially many synonymous mRNA sequences encoding the same protein. The present disclosure presents embodiments of a linear-time approximation (LinearDesign) reducing the design to an intersection between a Stochastic Context Free Grammar (SCFG) and a Deterministic Finite Automaton (DFA). Embodiments of the LinearDesign may implement an mRNA sequence design using much reduced time with very limited loss. Various methodologies, e.g., finding alternative sequences based on k-best parsing or directly incorporating codon optimality, are presented for incorporating the codon optimality into the design. Embodiments of the LinearDesign may provide efficient computational tools to speed up and improve mRNA vaccine development.
Absstract of: EP4682160A1
The present invention relates to a protein and a vaccine against infections by a SARS-CoV-2 Omicron variant XBB and subvariants thereof, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic agents against the infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof, the present invention provides proteins and vaccines against infections by the variants, the vaccines are designed based on the full-length S protein, the receptor-binding domain (RBD) sequence and optimized sequences of SARS-CoV-2 Omicron variant XBB and subvariant XBB.1.5, thereof, which are are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron variant XBB and subvariants thereof.
Absstract of: US20260014247A1
The present disclosure provides a composition for inducing or maintaining an immune response against SARS-COV-2 virus.
Absstract of: US20260014248A1
The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5′-UTR and/or a 3′-UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.
Absstract of: US20260014249A1
Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.
Absstract of: US20260014245A1
The present invention relates to a mutant receptor-binding domain (MERS-mRBD) of MERS-CoV (middle east respiratory syndrome coronavirus) or a fragment thereof and/or a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof having a reduced binding strength to the RBD-receptor DPP4 (dipeptidylpeptidase 4) of MERS-CoV compared to the wild type receptor-binding domain of MERS-CoV (MERS-wtRBD) and/or having a reduced binding strength to sialic acid compared to a wild type spike of MERS-CoV (MERS-wtSpike). Furthermore, the present invention relates to and a nucleic acid comprising a nucleotide sequence encoding for the MERS-mRBD or the fragment thereof or the MERS-mSpike or the fragment thereof and a vaccine composition comprising one or more MERS-mRBDs or fragments thereof, one or more MERS-mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention, as well as methods for prevention and/or treatment of diseases caused by MERS-CoV in a subject.
Absstract of: WO2026015635A1
The present invention provides methods, assays and kits for evaluation and assessment of IP-10 (CXCL10) expression, particularly IFN induction of IP-10, to determine the presence of inborn errors of the Type I IFN or Type II IFN response pathway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs or Type II IFNs in a patient. The methods, assays and kits including for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine-associated disease and adverse events, and for evaluation, treatment and management of patients, particularly including those who develop vaccine-associated disease. Identification of inborn errors of the Type 1 IFN response pathyway and/or auto-antibodies directed against, and particularly neutralizing, Type I IFNs are associated with severe viral illness, including COVID-19 disease, and vaccine-associated disease, particularly with live attenuated virus vaccines, particularly including yellow fever vaccines, as well as arboviral diseases, including WNV and TSE encephalitis.
Absstract of: WO2026015035A1
The invention relates to a portable exoskeleton for an upper limb, with n DOF (degrees of freedom), for patients recovering physically from COVID-19, having n DOF, wherein said exoskeleton comprises rigid plates on the outside of the arm which are rigid parts arranged in the upper part; joints (elbow, shoulder, clavicle) which connect the rigid plates and allow their movement in all directions in the form of flexion, extension, abduction, adduction, internal and external rotation; guides arranged on top of each of the rigid plates from the back to the forearm; bus cables for information, which pass through the guides starting from the end of the forearm up to the back; supports (straps) located on rigid plates of the exoskeleton, which secure the structure to the body; sensors connected to the information bus cables which terminate in the embedded system which are arranged in the rigid plates of the linkage points or rigid plates suitably located along the entire arm.
Absstract of: AU2025283415A1
Abstract Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes of cool or warm white light and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen. Abstract ec b s t r a c t e c
Absstract of: US20260016473A1
The present invention relates to a compound represented by the following general formula (1), or a salt or solvate thereof:in the formula (1), R1, R2, and R3 are as defined in the description.
Absstract of: US20260015770A1
Provided herein are compositions comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells and plasmablasts. Also provided are methods of using the RPPs.
Absstract of: US20260015337A1
The present invention is generally directed to inhibitors of SARS-CoV-2-related 3C-like protease (Mpro) useful in the treatment of coronavirus infection and having the Formula (A):
Absstract of: US20260015332A1
The present invention discloses the synthetic methods and the corresponding applications of a benzothiaselenazole-1-oxide compound and derivatives thereof, in which with sulfoximine and elemental selenium as starting materials, a series of benzothiaselenazole-1-oxide compounds has been synthesized through rhodium-catalyzed direct C—H functionalization reaction. Furthermore, with sulfoximine and elemental selenium as starting materials, a chiral benzothiaselenazole-1-oxide compound is synthesized through direct C—H functionalization reaction by virtue of a chiral phosphoric acid ligand. The present invention can allow specific labeling of sulfydryl structures in polypeptides, carbohydrates, drug molecules, and proteins, as well as in proteins and other biomacromolecules, exhibiting good anti-SARS-CoV-2 activity; and a bioconjugate with trastuzumab according to the present invention can effectively image HER2 receptors on the cell surface and show intense fluorescence, and is applicable to the preparation of an imaging reagent for the HER2 receptors on the cell surface.
Absstract of: WO2024187121A1
Disclosed herein are methods of treating and/or preventing a coronavirus infection using a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent. Also provided herein are therapeutic combinations comprising a peptide that binds to a SARS-CoV-2 spike protein and an additional therapeutic agent.
Absstract of: WO2024187120A1
Disclosed herein are dry powders, anhydrous compositions, and emulsions comprising a peptide that binds to a SARS-CoV-2 spike protein. The dry powders, anhydrous compositions, and emulsions disclosed herein are useful for the treatment and/or prevention of a coronavirus infection.
Absstract of: AU2024231716A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.
Absstract of: EP4678663A1
A fully human ACE2-Fc fusion protein, a pharmaceutical composition, preparation and kit containing same, and a nasal spray containing the fusion protein. Also provided is a use of the fusion protein for broad-spectrum prevention of coronavirus infections, such as infections with coronavirus SARS-CoV-2 and known and unknown variants thereof, including but not limited to original Hu-1, alpha, beta, gamma, delta, mu, omicron, JN.1, and/or other future strains. Also provided are a method for producing the fusion protein, and a method for using the fusion protein to prevent and/or treat infections with coronavirus SARS-CoV-2 and known and unknown variant strains thereof. Further provided is a use of the fusion protein and the pharmaceutical composition and preparation containing same for preventing the spread of coronavirus SARS-CoV-2 and known and unknown variant strains in infected subjects.
Absstract of: US20260009789A1
Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.
Absstract of: WO2026010909A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Absstract of: WO2026009244A1
The present invention relates to an electron-based apparatus for indoor air sterilization and purification, designed to neutralize airborne and surface-bound pathogens including viruses, bacteria, and fungi. The apparatus comprises a housing formed by an end cap (101), deco ring (102), top cover (103), bottom plate (108), and base ring (109), enclosing electron emitters mounted on a bobbin (104) and electrically connected via a 3 wire ring (105). A hypercharged electron cannon emits trillions of high-velocity, negatively charged electrons per second, which interact with viral spike proteins and microbial membranes, disrupting pathogen structure and infectivity without using filters, UV, or chemicals. A control box (106) and panel board (107) regulate emission parameters. The system supports plug-and-play operation, remote control, and requires no maintenance. Validated in virology and microbiology labs, it shows significant reductions in SARS-CoV-2 and other microbial loads. The apparatus is suitable for residential, commercial, and medical use, offering a safe and effective disinfection solution.
Absstract of: AU2024309711A1
The present relates to novel dihydroorotate dehydrogenase (DHODH) inhibitors of Formula (I) having a carboxylic acid, carboxamide or a bioisosteric moiety and being optionally deuterated, pharmaceutical formulations comprising them, a process for their preparation and their use as medicament, alone or in combination with one or more additional agents, for treating of various diseases, wherein the inhibition of DHODH is desirable (e.g. SARS-CoV-2 or IDH-mutated cancers).
Nº publicación: AU2024300009A1 08/01/2026
Applicant:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY
Absstract of: AU2024300009A1
Disclosed are bispecific antibodies, including dual variable domain immunoglobulins that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.
BOPI
Electronic site
